Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2022 at "Journal of Clinical Pharmacology"
DOI: 10.1002/jcph.2153
Abstract: Capmatinib is a highly specific, potent, and selective mesenchymal–epithelial transition factor inhibitor predominantly eliminated by cytochrome P450 (CYP) 3A4 and aldehyde oxidase. Here, we investigated the effects of a strong CYP3A inhibitor (itraconazole) and a… read more here.
Keywords: day; inhibition; coadministration; concentration ... See more keywords
The selective c-Met inhibitor capmatinib offsets cisplatin-nephrotoxicity and doxorubicin-cardiotoxicity and improves their anticancer efficacies.
Sign Up to like & getrecommendations! Published in 2020 at "Toxicology and applied pharmacology"
DOI: 10.1016/j.taap.2020.115018
Abstract: The incorporation of mesenchymal-epithelial transition factor (c-Met) inhibitors with conventional chemotherapeutics may increase the anticancer efficacy of chemotherapeutic agents, but bears the risk of enhancing the adverse effects. To test the hypothesis, co-administration of the… read more here.
Keywords: capmatinib; cardiotoxicity; inhibitor capmatinib; dox ... See more keywords
Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET‐dysregulated solid tumours
Sign Up to like & getrecommendations! Published in 2022 at "British Journal of Clinical Pharmacology"
DOI: 10.1111/bcp.15544
Abstract: Preclinical studies showed that capmatinib reversibly inhibits cytochrome P450 (CYP) 3A4 and CYP1A2 in a time‐dependent manner. In this study, we evaluated the effect of capmatinib on the exposure of sensitive substrates of CYP3A (midazolam)… read more here.
Keywords: substrates cyp3a; cyp1a2 caffeine; capmatinib; midazolam cyp1a2 ... See more keywords
Abstract CT082: Capmatinib inMETex14-mutated (mut) advanced non-small cell lung cancer (NSCLC): Results from the phase II GEOMETRYmono-1study, including efficacy in patients (pts) with brain metastases (BM)
Sign Up to like & getrecommendations! Published in 2020 at "Cancer Research"
DOI: 10.1158/1538-7445.am2020-ct082
Abstract: Background: Capmatinib is a highly selective and potent MET inhibitor that crosses the blood-brain barrier. In the GEOMETRY mono-1 study, capmatinib showed clinically meaningful response rates in pts with advanced NSCLC harboring METex14 skipping mutations,… read more here.
Keywords: capmatinib; efficacy; mut; geometry ... See more keywords
Abstract CT559: Capmatinib plus osimertinib vs platinum-pemetrexed doublet chemotherapy as second-line therapy in patients with stage IIIB/IIIC or IV EGFR-mutant, T790M-negative NSCLC harboring MET amplification
Sign Up to like & getrecommendations! Published in 2022 at "Cancer Research"
DOI: 10.1158/1538-7445.am2022-ct559
Abstract: Background: MET amplification can arise as a bypass resistance mechanism to EGFR tyrosine kinase inhibitors (TKIs) and occurs in ~5-26% of EGFR TKI resistant EGFR-mutant non-small cell lung cancer (NSCLC). These patients (pts) have limited… read more here.
Keywords: egfr mutant; capmatinib; osimertinib platinum; egfr ... See more keywords
Capmatinib Triggers Responses in NSCLC.
Sign Up to like & getrecommendations! Published in 2019 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-nb2018-148
Abstract: A phase II trial of the MET inhibitor capmatinib found that 72% of treatment-naïve patients responded to the drug, whereas the response rate for previously treated patients was 39.1%. The drug's side effects include peripheral… read more here.
Keywords: triggers responses; capmatinib triggers; responses nsclc; capmatinib ... See more keywords
Capmatinib for non-small cell lung cancer.
Sign Up to like & getrecommendations! Published in 2021 at "Drugs of today"
DOI: 10.1358/dot.2021.57.1.3239638
Abstract: Molecular profiling of non-small cell lung cancer (NSCLC) in the past decade has revealed numerous oncogenic driver events in NSCLC leading to several highly effective therapies. While a promising target, small-molecule inhibition of MET signaling… read more here.
Keywords: non small; capmatinib; cell lung; lung cancer ... See more keywords